יורוקינאז מדאק 100000 iu
tzamal bio-pharma ltd - urokinase - אבקה להכנת תמיסה לזריקה - urokinase 100,000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.
יורוקינאז מדאק 250000 iu
tzamal bio-pharma ltd - urokinase - אבקה להכנת תמיסה לזריקה - urokinase 250000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.
יורוקינאז מדאק 500000 iu
tzamal bio-pharma ltd - urokinase - אבקה להכנת תמיסה לזריקה - urokinase 500000 iu - urokinase - urokinase - peripheral arterial thrombosis ;acute and subacute deep vein thrombosis ; acute diagnostically confirmed pulmonary embolism, in particular when associated with unstable haemodynamic status ; thrombosed arteriovenous shunt.
מיוזיים
sanofi israel ltd - alglucosidase alfa - אבקה להכנת תרכיז לאינפוזיה - alglucosidase alfa 50 mg/vial - alglucosidase alfa - alglucosidase alfa - myozyme is indicated for long-term enzyme replacement therapy (ert) in patients with a confirmed diagnosis of pompe disease (acid alpha-glucosidase deficiency). the benefits of myozyme in patients with late-onset pompe disease have not been established.
אללייזו
pfizer pharmaceuticals israel ltd - taliglucerase alfa - אבקה להכנת תמיסה לאינפוזיה - taliglucerase alfa 200 u/vial - taliglucerase alfa - taliglucerase alfa - elelyso (taliglucerase alfa ) for injection is a hydrolytic lysosomal glucocerebroside - specific enzyme indicated for long - term enzyme replacement therapy (ert) for adults with a confirmed diagnosis of type 1 gaucher disease.
גונאל - אף
merck serono ltd - follitropin alfa - תמיסה להזרקה - follitropin alfa 600 iu/ml - follitropin alfa - follitropin alfa - gonal-f followed by chorionic gonadotrophin (hcg), is recommended for the stimulation of follicular development and ovulation in women with hypothalamic-pituitary dysfunction who present with either oligomenorrhoea or amenorrhoea. these women are classified as w.h.o group ii patients and usually receive clomiphene citrate as primary therapy. they have evidence of endogenous oestrogen production and thus will either spontaneously menstruate or experience withdrawal bleeding after progestagen administration. polycystic ovarian disease (pcod) is part of the who ii classification and is present in the majority of these patients. 2) gonal-f is indicated for stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertillization (ivf), gamete intra-fallopian transfer (gift) and zogote intra-fallopian transfer (zift). 3) gonal-f is indicated with concomitant human chorionic gonadotrophin (hcg) therapy for the stimulation of spermat
אלפא די 3 0.25 מקג
teva pharmaceutical industries ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 0.25 mcg - alfacalcidol
אלפא די 3 0.25 מקג
teva pharmaceutical industries ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 0.25 mcg - alfacalcidol
אלפא די 3 1.0 מקג
teva pharmaceutical industries ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 1 mcg - alfacalcidol
אלפא די 3 0.5 מקג
truemed ltd, israel - alfacalcidol - קפסולות ג'לטין רכות - alfacalcidol 0.5 mcg - vitamin d and analogues - renal bone disease . hypoparathyroidisim. rickets and osteomalacia. osteoporosis. primary and tertiary hyperparathyroidism. neonatal hypocalcemia.